Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aripiprazole - Bristol-Myers Squibb/Otsuka Pharmaceutical

Next Previous
Drug Profile

Aripiprazole - Bristol-Myers Squibb/Otsuka Pharmaceutical

Alternative Names: Abilify; Abilify Asimtufii; ABILIFY MAINTENA; Abilify Maintena; Abilify MyCite; ABILIFY MYCITE; Abilitat; Ao Pai; Aripiprazole depot - Otsuka Pharmaceutical/Lundbeck; Aripiprazole ECER tablets; Arlemide; Asimtufii; OPC-14597; OPC-14597 IMD; OPC-31

Latest Information Update: 24 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Otsuka Pharmaceutical
  • Developer Bristol-Myers Squibb; Indiana University; Lundbeck A/S; Otsuka Pharmaceutical
  • Class Antidepressants; Antipsychotics; Behavioural disorder therapies; Chlorobenzenes; Mood stabilisers; Piperazines; Quinolines; Small molecules
  • Mechanism of Action Alpha 1 adrenergic receptor antagonists; Dopamine D2 receptor partial agonists; Dopamine D3 receptor antagonists; Dopamine D4 receptor antagonists; Histamine H1 receptor antagonists; Serotonin 1A receptor partial agonists; Serotonin 2C receptor partial agonists; Serotonin 5-HT2A receptor antagonists; Serotonin 7 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gilles de la Tourette's syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Autistic disorder; Bipolar disorders; Gilles de la Tourette's syndrome; Major depressive disorder; Schizophrenia
  • Phase III Agitation; Pervasive child development disorders; Post-traumatic stress disorders
  • Discontinued Attention-deficit hyperactivity disorder; Psychotic disorders

Most Recent Events

  • 20 Jan 2025 Registered for Bipolar disorders in Canada (IM, Controlled release, q2month),
  • 20 Jan 2025 Registered for Schizophrenia in Canada (IM, Controlled release, q2month),
  • 02 May 2023 Regulatory submission withdrawn for Schizophrenia in European Union (IM, Controlled release,once every two months)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top